"70后"湖北富豪做医药"卖水人",百普赛斯年入8亿又要IPO了!

野马财经
Oct 08

在生物医药实验室里,几乎每一款新药从靶点验证走到临床试验,背后都有一种肉眼几乎看不见的“原料”始终在场——重组蛋白。药企做靶点确认、抗体筛选、细胞功能实验时,离不开它;而一旦进入规模化生产,对这类关键试剂的质量与稳定性要求,只会更高。把这种“卖水”生意做到全球前列的,是一家总部在北京的公司百普赛斯(301080.SZ,品牌ACROBiosystems)。在全球重组蛋白市场,它已是中国供应商中的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10